NasdaqGS:CRNXPharmaceuticals
Crinetics Pharmaceuticals (CRNX): Valuation in Focus After Key Phase 3 Paltusotine Trial Milestone
Crinetics Pharmaceuticals (CRNX) just hit an important milestone in its pipeline, announcing that the first patient has been randomized in the pivotal Phase 3 CAREFNDR trial for paltusotine in carcinoid syndrome.
See our latest analysis for Crinetics Pharmaceuticals.
Crinetics Pharmaceuticals’ momentum seems to be shifting after a challenging start to the year. The company’s recent Phase 3 trial announcement comes on the heels of a 42% share price gain over the past 90 days, helping offset...